2026 Clinical Research Marketing 
Advarra
AUGUST 8, 2024
The EU AI Act’s implications extend into clinical research, where AI is increasingly utilized for tasks like medical image analysis, natural language process for endpoint analysis, and generating/analyzing data for synthetic control arms. Non-EU companies must comply with the AI Act if their AI systems are used in the EU market.
Drug Discovery World
JANUARY 25, 2023
The logistics of DCTs The number of clinical trials being conducted via the DCT and hybrid model has increased significantly in recent years, and the pace of change shows no sign of slowing. The market, worth an estimated $8.8 billion, by 2026 1. billion in 2021 is expected to increase by 10% year on year, to $14.2
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Agency IQ
AUGUST 16, 2024
FDA released a draft guidance in June 2023 attempting to address many of these unique aspects of clinical research on psychedelic substances. The study is planned to begin in 2026 and conclude in 2028. Read AgencyIQ analysis here for a detailed discussion of these issues. ]. See AgencyIQ’s analysis of the draft guidance here. ].
Drug Discovery World
JULY 1, 2024
billion) in 2023, 51% higher than 2022, marking the company’s largest annual net profit going back to 1989, according to data from S&P Global Market Intelligence 1. According to the Washington Post 2 , Novo Nordisk turned an annual profit of 83.7 billion DKK ($11.97 million).
Drug Discovery World
FEBRUARY 26, 2024
And it’s not just bit.bio – there are many other companies exploring different cell types within clinical research. Challenges “There are some cell therapies on the market but the cost of those is maybe $500,000 a dose. One of these is cost, driven largely by the bespoke and expensive manufacturing processes.
The Pharma Data
NOVEMBER 11, 2020
market for the alfa pump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years. The heart failure market for the alfa pump DSR (Direct Sodium Removal) is estimated to be over €5 billion annually in the U.S. and EU5 by 2026. In the U.S., and Canada.
The Pharma Data
DECEMBER 16, 2020
market for the alfa pump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years. The heart failure market for the alfa pump DSR (Direct Sodium Removal) is estimated to be over €5 billion annually in the U.S. and EU5 by 2026. In the U.S., and Canada.
Expert insights. Personalized for you.
52 
Let's personalize your content